Disease & Strategy
SGCE gene, imprinting, pathophysiology, and therapeutic approach
Genetic Identity
Primary Variant — SGCE (Pathogenic)
Likely Pathogenic Variant (LPV)- Transcript
- NM_003919.3
- DNA change
- c.108dup
- Protein effect
- p.Val37SerfsTer32
- Mechanism
- 1 bp duplication in exon 3 → reading frame shift → NMD → complete protein loss
- Inheritance
- Autosomal dominant, maternally imprinted (paternal allele affected)
Secondary Variant — THAP1 (VUS)
Variant of Uncertain Significance- Transcript
- NM_018105.3
- DNA change
- c.496G>A
- Protein effect
- p.Ala166Thr
Therapeutic Strategy
Primary Strategy
AAV Gene Replacement
Mutation-agnostic. Delivers full-length functional protein via episomal transgene. Strong CNS clinical precedent.
Secondary Strategy
Maternal Allele De-repression
Reactivate the silenced wildtype maternal allele via targeted epigenetic editing (dCas9-TET1 or ASO).
Long-term Watch
Prime Editing
The only editing tool capable of deleting a 1 bp insertion. Could correct c.108dup at the genomic level.
Transient / Backup
mRNA (LNP)
Repeat-dose mRNA delivery. No genome modification. Limited by CNS penetration and dosing frequency.
Comparative Analysis
| Criterion | AAV Replacement | Epigenetic Reactivation | Prime Editing | mRNA (LNP) |
|---|---|---|---|---|
| Implementation complexity | Low | Medium | Very High | Very High |
| CNS clinical validation | Strong | Preclinical | Preclinical | Early |
| Genome modification | None | Epigenome only | 1 nt deletion | None |
| Durability (single dose) | Lifelong* | Uncertain | Lifelong* | Transient |
| Vector packaging | Single AAV | N/A | Dual AAV | LNP |
| Off-target risk | Minimal | Moderate | Moderate | Low |
| Compatible with c.108dup | Yes | Yes | Yes | Yes |
* In post-mitotic neurons. AAV episomal DNA persists without cell division.